title: Trastuzumab emtansine for HER2-positive breast cancer.
authors.forename: Priya
authors.initials: P
authors.lastname: Venkatesan
mesh_terms: D000080044:Ado-Trastuzumab Emtansine; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors* / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000401:mortality / Q000473:pathology; D017326:Clinical Trials, Phase III as Topic; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008453:Maytansine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000068878:Trastuzumab / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D050257:Tubulin Modulators / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000080044:Ado-Trastuzumab Emtansine; D000074322:Antineoplastic Agents, Immunological; D014408:Biomarkers, Tumor; D008453:Maytansine; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; D050257:Tubulin Modulators; C508053:ERBB2 protein, human